Select Bibliography

Filter by any of these (after searching):

Socinski, M. A.

AUTHOR ABSTRACT DEADLINES

A meeting abstract must be submitted by the first or corresponding author to the Alliance Publications Coordinator (publications@AllianceNCTN.org) at least two weeks prior to the meeting abstract submission deadline. For detailed information about Alliance Publications guidelines, please refer to the policies, along with the author abstract deadlines.

There are 7 items

Induction (Ind) plus concurrent (Con) chemotherapy with high-dose (74 Gy) 3-dimensional (3-D) thoracic radiotherapy (TRT) in stage III non-small cell lung cancer (NSCLC): Preliminary report of Cancer and Leukemia Group B (CALGB) 30105

Blackstock, A. W. , Socinski, M. A. , Bogart, J. , Gu, L. , Wang, X. ... - - J Clin Oncol - 2006

Abstract - Primary - Primary - Respiratory - CALGB-30105

Dose-dense weekly paclitaxel (P) in extensive stage small cell lung cancer (ES-SCLC): Cancer and Leukemia Group B (CALGB) 39901

Graziano, S. L. , Socinski, M. A. , Herndon, J. E., 2nd ... - - Proc Am Soc Clin Oncol - 2003

Abstract - Primary - Primary - Respiratory - CALGB-39901

CALGB 30704: A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC)

Heist, R. C. Suk , Wang, X. , Hodgson, L. D. , Otterson, G. A. ... - ASCO - J Clin Oncol - 2012

Abstract - Primary - Primary - Respiratory - CALGB-30704

Randomized phase II trial of erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in never or light former smokers with advanced lung adenocarcinoma: CALGB 30406

Janne, P. A. , Miller, V. A. , Wang, X. , Socinski, M. A. ... - ASCO - J Clin Oncol - 2010

Abstract - Primary - Primary - Respiratory - CALGB-30406

Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial

Janne, P. A. , Wang, X. F. , Socinski, M. A. , Crawford, J. ... - - J Clin Oncol - 2012

Manuscript - Primary - Primary - Respiratory - CALGB-30406

Outcome of advanced NSCLC patients with EGFR exon 19 and 21 mutations treated with erlotinib (E) alone or in combination with carboplatin/paclitaxel (CP) in CALGB 30406

Janne, P. A. , Wang, X. , Socinski, M. A. , Crawford, J. , Gu, L. ... - IASLC (WCLC) - J Thorac Oncol - 2011

Abstract - Secondary - Primary - Respiratory - CALGB-30406

An analysis of the prevalence of HER2 and KRAS mutations, and ALK rearrangements and clinical outcomes in Cancer and Leukemia Group B [CALGB (Alliance)] trial 30406 in advanced non-small cell lung cancer (NSCLC)

Stinchcombe, T. E. , Sholl, L. M. , Wang, X. , Gu, L. ... - ASCO - J Clin Oncol - 2013

Abstract - Secondary-not-in-original - Primary - Respiratory - Alliance-30406